



Published in final edited form as:

Science. 2001 April 20; 292(5516): 449–451. doi:10.1126/science.1060849.

How Do Cells Sense Oxygen?

Hao Zhu and H. Franklin Bunn

Hematology Division of the Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. zhu@calvin.bwh.harvard.edu, bunn@calvin.bwh.harvard.edu

Abstract

How do organisms sense the amount of oxygen in the environment and respond appropriately when the amount of oxygen decreases (a condition called hypoxia)? In a Perspective, Zhu and Bunn discuss new findings (Ivan *et al.*, Jaakkola *et al.*) that reveal how the hypoxia inducible factor transcription factor, which switches on a group of hypoxia-response proteins, is itself regulated by changes in oxygen tension.

In the early 20th century, the fledgling disciplines of physiology and biochemistry became interested in how animals and cells respond to changes in the amount of oxygen in their environment (oxygen homeostasis). Since then, much has been learned about how the cardiovascular and respiratory systems adjust to low oxygen tensions in tissues (hypoxia), how changes in tissue oxygen tension affect cellular metabolism and, within the last decade, how hypoxia affects programs of gene expression. But there is still much to learn about the ways in which cells sense reduced oxygen tensions and activate signal transduction pathways that lead to physiologically appropriate changes in gene expression. Papers by Ivan *et al.* (1) and Jaakkola *et al.* (2) in this week's *Science Express* add considerably to our understanding of this process by unraveling how a transcription complex, hypoxia inducible factor (HIF), controls gene expression in response to changes in oxygen tension.

When mammalian tissues are challenged by hypoxia, the expression of a number of physiologically important proteins is increased. For example, there is increased production of erythropoietin, a cytokine required for the formation of red blood cells; an increase in the number of erythrocytes enhances the delivery of oxygen to tissues. Vascular endothelial growth factor (VEGF) is a key regulator of blood vessel growth (angiogenesis). The induction of VEGF expression in hypoxic tissues results in enhanced blood flow, thereby providing protection against ischemic injury. VEGF is also important for tumor angiogenesis (3). Tyrosine hydroxylase is the rate-limiting enzyme in dopamine synthesis. The upregulation of this enzyme in glomus cells of the carotid body in the neck enables the hypoxic animal to achieve a sustained increase in ventilation. Hypoxia also induces synthesis of certain glycolytic enzymes, enabling intracellular levels of the energy-rich molecule adenosine triphosphate to be maintained.

In hypoxic cells, the upregulation of these and many other proteins depends on the activation of the HIF family of transcription factors (3). Heterodimers composed of HIF α and HIF β subunits bind to pentanucleotide (5'-RCGTG-3') response elements in genes encoding the proteins upregulated in response to hypoxia. The HIF subunits are members of the PAS protein family, which includes not only transcription factors but other proteins that sense perturbations in a cell's environment. For example, FixL in *Rhizobium* bacteria, a heuristic distant relative of PAS family members, is an oxygen-sensing fusion protein containing a heme binding domain and a protein kinase domain (4).

The HIF subunits are widely, perhaps universally, expressed in the cells and tissues of mammals, flies, worms and probably most other creatures. The β subunit, commonly called ARNT (arylhydrocarbon nuclear translocator), is a partner for the arylhydrocarbon receptor and is abundantly expressed independently of oxygen tension. In contrast, HIF α (5) cannot be detected unless cells are challenged by hypoxia. Above a critical intracellular oxygen tension, HIF α is rapidly degraded in cellular organelles called proteasomes following its ubiquitination (a process in which ubiquitin molecules are added to proteins to tag them for degradation) (see the figure). HIF α contains an oxygen-dependent degradation domain (6) within which is a highly conserved region (7) containing a binding site for the tumor suppressor von Hippel-Lindau protein (pVHL) (8–10). The pVHL organizes the assembly of a complex that activates the ubiquitin E3 ligase, which then ubiquitinates HIF α targeting it for degradation. Interestingly, mutations in pVHL (encountered in certain tumors) prevent it from binding to HIF α , causing constitutive expression of this transcription factor and its target genes. Such mutations increase the potential for angiogenesis, probably through the continued production of VEGF (11,12).

The nature of the oxygen sensor that regulates the activity of HIF remains elusive. There is circumstantial evidence implicating the participation of a heme protein (13) that generates reactive oxygen species (14). Besides hypoxia, HIF can also be activated by the transition metal cations Co^{2+} , Ni^{2+} , and Mn^{2+} and also by reagents that chelate iron. These observations hint that HIF α might be oxidatively modified by reactive oxygen species generated through a nonenzymatic oxygen- and iron-dependent process akin to that previously described for both bacterial and mammalian enzymes (15). However, if highly labile reactive oxygen species serve as messengers regulating HIF α activity, it is likely that shortrange interactions are involved, requiring the participation of an enzyme. This concern is squarely addressed by Ivan *et al.* (1) and Jaakkola *et al.* (2). With a remarkable degree of accord, they provide convincing evidence that a prolyl hydroxylase enzyme encountered in a variety of mammalian cells is involved in sensing oxygen. In the presence of oxygen and iron, this enzyme targets a highly conserved residue in human HIF-1 α , proline 564, and hydroxylates it (attaches an OH group). Hydroxylation of this proline appears to be both necessary and sufficient for the binding of pVHL to HIF α .

The immediate challenge is to isolate and further characterize the HIF α prolyl hydroxylase. Like the well-studied collagen prolyl 4-hydroxylases (16), the HIF-modifying enzyme depends on both oxygen and iron. Furthermore, the collagen and HIF enzymes respond to similar cofactors and inhibitors (2). However, collagen prolyl 4-hydroxylases are localized within the endoplasmic reticulum of the cell, whereas the HIF oxygen sensor is very likely to be cytosolic. Moreover, the two differ considerably in their interactions with oxygen. Hydroxylation of proline in collagen is insensitive to a wide range of oxygen concentrations, whereas the HIF oxygen sensor must have a considerably lower affinity for oxygen, enabling it to respond to subtle alterations in intracellular oxygen tension.

It will be important to learn whether there are other substrates for the HIF prolyl hydroxylase. Does the pVHL-dependent ubiquitination and degradation of other proteins depend on proline hydroxylation? Does the HIF prolyl hydroxylase control the hypoxia-dependent transcriptional activation of HIF α as well as of other transcription factors? These issues of specificity bear on whether it will be possible to develop drugs that target the oxygen sensing and signaling pathways that regulate HIF activity in response to hypoxia in clinical diseases. In particular, the controlled and local induction of VEGF by HIF could greatly enhance recovery from heart attacks or cerebral strokes. Conversely, tumorspecific suppression of VEGF would be expected to limit the growth and spread of malignancies.

The identification of HIF prolyl hydroxylase begs the question of whether other classes of proteins serve as oxygen sensors, and if so, whether they could be implicated in HIF activation? Candidates include flavoheme oxidoreductases (14), such as the recently identified cytochrome b5/b5 reductase fusion protein (17). An NADPH (reduced form of nicotinamide adenine dinucleotide phosphate) oxidase containing gp91^{phox} behaves as an oxygen sensor in pulmonary neuroepithelial bodies (18). These challenges appeal to a broad range of research disciplines and doubtless will be met in the near future.

Oxygen-dependent regulation of the HIF transcription factor

When the intracellular oxygen tension reaches a critical threshold, newly synthesized HIF α subunits (α) are oxidatively modified by a prolyl hydroxylase (PH) enzyme. This iron-dependent process results in the hydroxylation of a specific proline residue within a highly conserved region of the HIF α 's internal oxygen-dependent degradation domain. This structural modification is necessary and sufficient for binding of HIF α to pVHL, which mediates the assembly of a complex (UL) that activates the ubiquitin-E3 ligase. Ubiquitination of HIF α is necessary for this transcription factor to be degraded by the proteasome. When cells are hypoxic (that is, the intracellular oxygen tension decreases below a critical threshold), the proline is not hydroxylated and so HIF α escapes degradation. HIF α then forms a stable heterodimer with HIF β (ARNT). The HIF $\alpha\beta$ heterodimer translocates to the nucleus, where it binds to hypoxia response elements in genes that are switched on by hypoxia.

References and Notes

- Ivan M, et al. *Science*. April 5;2001 (10.1126/science.1059817). Include this information when citing this paper.
- Jaakkola P, et al. *Science*. April 5;2001 (10.1126/science.1059796). Include this information when citing this paper.
- Semenza GL. *Annu. Rev. Cell Dev. Biol* 1999;15:551. [PubMed: 10611972]
- Gilles-Gonzalez MA, Ditta GS, Helinski DR. *Nature* 1991;350:170. [PubMed: 1848683]
- Mammalian HIF α includes HIF-1 α and its homolog HIF-2 α (EPAS1), which has a more limited range of tissue expression. Other HIF α homologs have been reported but are not known to be regulated by oxygen-dependent degradation.
- Huang LE, Gu J, Schau M, Bunn HF. *Proc. Natl. Acad. Sci. U.S.A* 1998;95:7987. [PubMed: 9653127]
- Srinivas V, Zhang L-P, Zhu X-H, Caro J. *Biochem. Biophys. Res. Commun* 1999;260:557. [PubMed: 10403805]
- Cockman ME, et al. *J. Biol. Chem* 2000;275:25733. [PubMed: 10823831]
- Ohh M, et al. *Nature Cell Biol* 2000;2:423. [PubMed: 10878807]
- Tanimoto K, Makino Y, Pereira T, Poellinger L. *EMBO J* 2000;19:4298. [PubMed: 10944113]
- Maxwell PH, et al. *Nature* 1999;399:271. [PubMed: 10353251]
- Ivan M, Kaelin WG. *Curr. Opin. Genet. Dev* 2000;11:27. [PubMed: 11163147]
- Goldberg MA, Dunning SP, Bunn HF. *Science* 1988;242:1412. [PubMed: 2849206]
- Kietzman T, Fandrey J, Acker H. *News Physiol. Sci* 2000;15:202. [PubMed: 11390911]
- Stadtman ER, Oliver CN. *J. Biol. Chem* 1991;266:2005. [PubMed: 1989966]
- Kivirikko KI, Pihlajaniemi T. *Adv. Enzymol. Related Areas Mol. Biol* 1998;72:325.
- Zhu H, Qiu H, Yoon HW, Huang S, Bunn HF. *Proc. Natl. Acad. Sci. U.S.A* 1999;96:14742. [PubMed: 10611283]
- Fu XW, et al. *Proc. Natl. Acad. Sci. U.S.A* 2000;97:4374. [PubMed: 10760304]